XML 21 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
INVENTORY
 9 Months Ended
Dec. 31, 2024
Inventory Disclosure [Abstract]  
Inventory Disclosure [Text Block]

NOTE 3 – INVENTORY

 

   (in thousands) 
  

As of
December 31,
2024
($)

  

As of
March 31,
2024
($)

 
Raw materials   1,069    1,099 
Work-in-Progress   -    - 
Finished goods   364    441 
Total   1,433    1,540 

 

Abnormal amounts of idle facility expense, freight, handling costs, scrap, and wasted material (spoilage) are expensed in the period they are incurred. During the nine months ended December 31, 2024, and 2023, the Company wrote off approximately $50 thousand and $746 thousand primarily related to obsolete and expired stock.

 

We capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative use for the inventory in future research and development projects or other purposes. As of December 31, 2024, and March 31, 2024, our consolidated balance sheet reported approximately $392 thousand clinical trial-related inventory, respectively.